167362-48-3
167362-48-3 structure
- Name: AbetiMus
- Chemical Name: AbetiMus
- CAS Number: 167362-48-3
- Molecular Formula:
- Molecular Weight:
- Catalog: Research Areas Inflammation/Immunology
- Create Date: 2018-06-19 07:24:49
- Modify Date: 2025-09-29 18:38:47
-
Abetimus (LJP 394 free base) is an immunosuppressant consisting of four double-stranded DNA (dsDNA) oligonucleotides. Abetimus is capable of crosslinking anti-dsDNA antibodies on the surface of B cells, and decreases anti-dsDNA antibodies levels. Abetimus has the potential for research of systemic lupus erythematosus[1].
| Name | AbetiMus |
|---|---|
| Synonyms | ABETIMUS |
| Description | Abetimus (LJP 394 free base) is an immunosuppressant consisting of four double-stranded DNA (dsDNA) oligonucleotides. Abetimus is capable of crosslinking anti-dsDNA antibodies on the surface of B cells, and decreases anti-dsDNA antibodies levels. Abetimus has the potential for research of systemic lupus erythematosus[1]. |
|---|---|
| Related Catalog | |
| In Vitro | Administration of Abetimus (LJP 394 free base) is thought to reduce circulating anti-dsDNA Abs by at least two mechanisms. First, Abetimus (LJP 394 free base) acutely depletes circulating anti-dsDNA antibodies, presumably by forming small, soluble complexes that do not appear to result in significant activation of the complement system. Second, Abetimus (LJP 394 free base) binds B cells without T-cell activation, resulting in their apoptosis and reduced anti-dsDNA antibody production. In fact, Abetimus (LJP 394 free base) appears to induce B-cell tolerance by crosslinking anti-dsDNA surface immunoglobulin receptors on B cells and triggering the signal transduction pathways that lead to B-cell anergy or apoptosis[1]. |
| In Vivo | Abetimus (LJP 394 free base) proves effective in suppressing anti-dsDNA-mediated pathologies in male BXSB mice, a model for systemic lupus. Mice dosed with Abetimus (3-300 μg/mouse) i.v. twice weekly, starting around nine weeks of age, has significantly lower titers of anti-dsDNA, lower numbers of anti-dsDNA-secreting spleen cells and less adverse renal histopathology than control mice[2]. Abetimus has a pharmacokinetic half-life ranging from 40 min to 1 h in mice[1]. |
| References |
| No Any Chemical & Physical Properties |